Optimal sequencing of enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Maughan, Benjamin Louis
Suzman, Daniel L.
Nadal, Rosa Maria
Bassi, Sunakshi
Antonarakis, Emmanuel S.
机构：
[1] Johns Hopkins Medcl Ctr, Baltimore, MD USA
[2] Johns Hopkins, Baltimore, MD USA
[3] NIH, Bldg 10, Bethesda, MD 20892 USA
[4] Johns Hopkins Univ, Baltimore, MD USA
[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 02期
关键词：
D O I：
10.1200/jco.2016.34.2_suppl.308
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
308
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [2] Optimal Sequencing of Docetaxel and Abiraterone in Men With Metastatic Castration-Resistant Prostate Cancer
    Maughan, Benjamin L.
    Xhou, Xian C.
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael T.
    Antonarakis, Emmanuel S.
    [J]. PROSTATE, 2015, 75 (15): : 1814 - 1820
  • [3] Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study
    Maughan, Benjamin L.
    Luber, Brandon
    Nadal, Rosa
    Antonarakis, Emmanuel S.
    [J]. PROSTATE, 2017, 77 (01): : 33 - 40
  • [4] Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study
    Azuma, Takeshi
    [J]. PROSTATE, 2018, 78 (04): : 278 - 278
  • [5] Effects of abiraterone acetate and enzalutamide on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)
    Ileana, Ecaterina
    Antoun, Sami
    Albiges, Laurence
    Massard, Christophe
    Di Palma, Mario
    Escudier, Bernard J.
    Fizazi, Karim
    Loriot, Yohann
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
  • [7] Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
    La, Jennifer
    Wang, Lin
    Corrigan, June K.
    Lang, Deborah
    Lee, Michelle H.
    Do, Nhan V.
    Brophy, Mary T.
    Paller, Channing J.
    Fillmore, Nathanael R.
    [J]. JAMA NETWORK OPEN, 2024, 7 (08)
  • [8] Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC): Effect of early docetaxel on outcomes.
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
    Zhang, Tian
    Zhu, Jason
    George, Daniel J.
    Armstrong, Andrew J.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 473 - 485
  • [10] Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer
    Banna, Giuseppe L.
    Urzia, Valeria
    Benanti, Chiara
    Pitre, Alessandra
    Lipari, Helga
    Di Quattro, Rosario
    De Giorgi, Ugo
    Schepisi, Giuseppe
    Basso, Umberto
    Bimbatti, Davide
    Rundo, Francesco
    Libra, Massimo
    Malatino, Lorenzo
    [J]. SUPPORTIVE CARE IN CANCER, 2020, 28 (10) : 4687 - 4695
12345